C

Celon Pharma SA
WSE:CLN

Watchlist Manager
Celon Pharma SA
WSE:CLN
Watchlist
Price: 20.2 PLN -1.94% Market Closed
Market Cap: 1.1B PLN

Net Margin
Celon Pharma SA

-53.4%
Current
-18%
Average
4.7%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-53.4%
=
Net Income
-122.1m
/
Revenue
228.6m

Net Margin Across Competitors

Country Company Market Cap Net
Margin
PL
Celon Pharma SA
WSE:CLN
1.1B PLN
-53%
US
Eli Lilly and Co
NYSE:LLY
939.8B USD
31%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
-4%
US
Johnson & Johnson
NYSE:JNJ
497B USD
27%
CH
Roche Holding AG
SIX:ROG
256.4B CHF
15%
UK
AstraZeneca PLC
LSE:AZN
209.6B GBP
16%
CH
Novartis AG
SIX:NOVN
202.3B CHF
26%
US
Merck & Co Inc
NYSE:MRK
242.8B USD
30%
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK
33%
IE
Endo International PLC
LSE:0Y5F
202.5B USD
-126%
US
Pfizer Inc
NYSE:PFE
146.6B USD
16%
No Stocks Found

Celon Pharma SA
Glance View

Market Cap
1.1B PLN
Industry
Pharmaceuticals

Celon Pharma SA is a pharmaceutical company, which engages in the research and manufacture of modern drugs. The firm focuses on research, development and production of generic drugs for cancer, neurological diseases, diabetes and other metabolic disorders treatment, among others. Its products portfolio comprises pills, such as Aromek, Bosentan Celon, Donepex, Ketrel, Lazivir and Valzek, as well as inhalation powder, such as Salmex. The firm's research center develops pharmaceuticals within a number of therapeutic areas, including oncology, neurology, as well as inflammatory and metabolic diseases. The firm is a subsidiary of Glatton sp z o o.

CLN Intrinsic Value
HIDDEN
Show
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-53.4%
=
Net Income
-122.1m
/
Revenue
228.6m
What is the Net Margin of Celon Pharma SA?

Based on Celon Pharma SA's most recent financial statements, the company has Net Margin of -53.4%.

Back to Top